Head to head
Pfizer vs Eli Lilly and Co
Side-by-side on the measures that matter, with a plain-English read. Full detail: PFE · LLY
PFE
Pfizer
27.61-1.39%
1-year price shape — +14% over the period
Quant Rating C · 55/100
vs
LLY
Eli Lilly and Co
1,143.39-3.81%
1-year price shape — +42% over the period
Quant Rating B · 79/100
1-year performance, rebased to 100
Eli Lilly and Co edges it on the scoreable measures. Eli Lilly and Co has the highest Quant Rating (79); Eli Lilly and Co has done best over the past year (+42%); Eli Lilly and Co earns the most per share.
| PFE | LLY | |
|---|---|---|
| Snapshot | ||
| Sector | -- | Drug Manufacturers - General |
| Last price | 27.61 | 1,143.39 |
| Change today | -1.39% | -3.81% |
| 1-year return | +14.1% | +41.8% |
| Market cap | $157.37B | $1.08T |
| 52-week range | 22.57 – 29.21 | 778.93 – 1,292.65 |
| Valuation | ||
| P/E (TTM) | 36.33 | 38.38 |
| P/E percentile, own 5-yr range | 92nd | 6th |
| P/B | 1.85 | 31.77 |
| Dividend yield | 6.23% | 0.56% |
| Profitability & growth | ||
| EPS (TTM) | 1.36 | 22.95 |
| Net profit (TTM) | $7.75B | $21.60B |
| Revenue (TTM) | $63.70B | $79.67B |
| Revenue growth (YoY) | +2.6% | +47.7% |
| Gross margin | 73.2% | 83.4% |
| Operating margin | 26.7% | 49.7% |
| Net margin | 6.8% | 33.5% |
| Free cash flow (TTM) | $10.99B | $13.56B |
| Ownership & sentiment | ||
| Institutional ownership | 68.4% | 79.5% |
| Insider activity (12mo) | 44 buy / 2 sell | 37 buy / 13 sell |
| Short interest (% of float) | 2.7% | 0.8% |
| Analyst consensus | 37% buy / 58% hold / 5% sell (19) | 91% buy / 5% hold / 5% sell (22) |
| Analyst price target | $29 (+5%) | $1,381 (+21%) |
| StockVane view | ||
| StockVane Quant Rating | C (55) | B (79) |
| Company | ||
| Employees | 75,000 | 50,000 |
| Founded | 1849 | 1876 |
▲ marks the more favourable stock(s) on measures with a clear direction (lower P/E, higher yield, higher Quant Rating, better 1-year return). Analyst consensus counts each covering institution once, at its most recent rating. Not a recommendation. Quant Rating method: Data & Methodology.